Alcohol Use Disorder: 8 Essential Primary Care Rules
Clinical Practice Update — Screening, Pharmacotherapy, and Withdrawal Management in Primary Care
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based alcohol use disorder screening, pharmacotherapy, and withdrawal management in adults
- Target Audience
- Family physicians, general practitioners, nurse practitioners, physician assistants, pharmacists
- Setting
- Primary care and outpatient family medicine
- Source Evidence
- •USPSTF 2018 — Screening and Behavioral Counseling Interventions for Unhealthy Alcohol Use
- •APA 2018 Practice Guideline — Pharmacological Treatment of Alcohol Use Disorder (Reus et al.)
- •VA/DoD 2021 Clinical Practice Guideline for Substance Use Disorders
- •ASAM 2020 Clinical Practice Guideline on Alcohol Withdrawal Management
Key Clinical Takeaways
Effective care for alcohol use disorder in primary care rests on three actions: routine screening with the AUDIT-C, confirming the diagnosis against DSM-5 criteria, and offering evidence-based pharmacotherapy paired with psychosocial support. Primary care is the single most important setting in which alcohol use disorder is identified — but it is also where treatment is most often under-offered. The rules below distil current USPSTF, APA, VA/DoD, and ASAM guidance into actions a busy clinician can take at the next appointment.
- 1Screen every adult at least annually using the AUDIT-C — a score of 4+ in men or 3+ in women or over 65s warrants full assessment → Screening
- 2Confirm the diagnosis of alcohol use disorder against DSM-5 criteria — 2–3 mild, 4–5 moderate, 6+ severe → Diagnosis
- 3Deliver brief counselling for risky drinking — short, structured interventions in primary care reliably reduce consumption → Brief Intervention
- 4Assess for comorbid depression, anxiety, trauma, and other substance use — co-occurrence is the rule, not the exception → Assessment
- 5Offer naltrexone or acamprosate as first-line pharmacotherapy for moderate-to-severe alcohol use disorder → Pharmacotherapy
- 6Consider gabapentin or topiramate (off-label) when first-line agents fail or are contraindicated → Second-Line
- 7Use CIWA-Ar to risk-stratify withdrawal — mild-moderate cases can be managed in the community with symptom-triggered benzodiazepines → Withdrawal
- 8Always prescribe thiamine 100 mg daily (oral or IM) for patients with heavy intake or suspected deficiency — prevent Wernicke’s before it happens → Withdrawal
Screening and Diagnosing Alcohol Use Disorder
The biggest missed opportunity in alcohol use disorder care is screening. The USPSTF recommends routine screening in all adults, yet fewer than one in six adults in primary care reports ever being asked about alcohol in a structured way. The AUDIT-C is a 3-question tool that fits inside a rooming workflow and validates against the full AUDIT and DSM-5 diagnosis.
Screen all adults, including pregnant persons, at least annually using the AUDIT-C. A score of 4 or more in men or 3 or more in women or adults over 65 warrants a full assessment including DSM-5 criteria.
Strong Rec High Evidence USPSTF 2018Confirm the diagnosis of alcohol use disorder against DSM-5 criteria. Severity grading follows: 2–3 symptoms → mild; 4–5 → moderate; 6 or more → severe. Severity directly informs treatment intensity.
Strong Rec High Evidence APA 2018 VA/DoD 2021Obtain a focused baseline workup: liver function (AST, ALT, GGT), CBC (looking for macrocytosis), metabolic panel, and a pregnancy test where relevant. Elevated MCV or GGT alone are not diagnostic but corroborate self-reported intake.
Moderate Rec Moderate Evidence VA/DoD 2021Deliver a structured brief intervention (5–15 minutes) at the index visit for anyone with a positive screen, using a validated framework such as FRAMES or the 5 A’s. Brief intervention reduces drinking volume in risky users by a meaningful margin.
Strong Rec High Evidence USPSTF 2018Screen for comorbid depression (PHQ-9), anxiety (GAD-7), PTSD, and concurrent substance use at diagnosis and at every follow-up. Around half of adults with alcohol use disorder have a co-occurring mental health condition that shapes treatment choice.
Strong Rec High Evidence APA 2018AUDIT-C Severity Bands and Primary Care Actions
| AUDIT-C Score | Risk Band | Primary Care Action | Review Interval |
|---|---|---|---|
| 0–2 (women/>65) / 0–3 (men) | Low risk | General advice on low-risk drinking limits | Annually |
| 3–5 / 4–5 | Risky use | Brief intervention; DSM-5 assessment | 3–6 months |
| 6–7 | Likely AUD | Full AUDIT, DSM-5, consider pharmacotherapy | 1–3 months |
| 8–12 | Severe AUD likely | Pharmacotherapy, referral, withdrawal risk assessment | 1–4 weeks |
Pharmacotherapy for Alcohol Use Disorder
Medication for alcohol use disorder is one of the most under-used evidence-based interventions in primary care. Fewer than 10% of adults with moderate-to-severe AUD receive pharmacotherapy in any given year, despite strong evidence that naltrexone and acamprosate reduce heavy drinking and relapse. Prescribing does not require a specialist license or abstinence as a precondition — these are first-line primary care medications.
Offer naltrexone 50 mg daily (oral) or 380 mg intramuscular monthly as first-line pharmacotherapy for moderate-to-severe alcohol use disorder. Naltrexone reduces heavy drinking days and craving, and does not require abstinence before starting.
Strong Rec High Evidence APA 2018 VA/DoD 2021Offer acamprosate 666 mg three times daily as an equivalent first-line alternative, particularly for patients aiming for complete abstinence or who are already abstinent. Dose-adjust in renal impairment and avoid if creatinine clearance is below 30 mL/min.
Strong Rec High Evidence APA 2018 Jonas 2014Consider gabapentin 900–1800 mg daily (in divided doses) or topiramate titrated to 200–300 mg daily as second-line options when naltrexone and acamprosate have failed or are contraindicated. Both are off-label but have reasonable evidence and are familiar to primary care.
Moderate Rec Moderate Evidence APA 2018 VA/DoD 2021Restrict disulfiram to carefully selected, motivated patients with a reliable support person to supervise dosing and a commitment to complete abstinence. Do not use disulfiram without informed consent about the severity of the alcohol-disulfiram reaction.
Conditional Rec Low Evidence APA 2018Pair pharmacotherapy with psychosocial treatment: cognitive behavioural therapy, motivational enhancement, 12-step facilitation, or mutual-support groups. Combining medication with psychosocial treatment produces additive effects on drinking outcomes.
Strong Rec High Evidence VA/DoD 2021Medications for Alcohol Use Disorder: A Drug-by-Drug Guide
The table below is organised by drug rather than by line of therapy — the layout clinicians actually need when choosing between options at the bedside. Every entry includes a practical tip drawn from common primary care pitfalls in managing alcohol use disorder.
| Drug | Dose | Best Suited For | Practical Tips and Cautions |
|---|---|---|---|
| Naltrexone (oral) | 50 mg once daily | Reducing heavy drinking; strong craving; first-line | Check LFTs at baseline and 4–12 weeks. Avoid with any opioid use or dependence; will precipitate withdrawal. |
| Naltrexone (IM, Vivitrol) | 380 mg IM every 4 weeks | Adherence concerns; high relapse risk | One appointment = one month of therapy. Same opioid caution as oral. |
| Acamprosate | 666 mg TID | Already abstinent; aiming to stay abstinent; liver disease | Renally cleared — dose-adjust if eGFR <50, avoid if <30. Three-times-daily dosing affects adherence. |
| Gabapentin (off-label) | 300–600 mg TID (total 900–1800 mg) | Protracted insomnia or anxiety in early recovery; second-line | Screen for misuse history. Dose-reduce in renal impairment. |
| Topiramate (off-label) | Titrate to 200–300 mg daily (divided) | Concurrent migraine; failed first-line | Slow titration (25 mg weekly). Monitor for cognitive side effects, paraesthesia, and metabolic acidosis. |
| Disulfiram | 250 mg daily | Highly motivated; supervised dosing available; select cases only | Severe reaction with even small alcohol exposure. Avoid in IHD, psychosis, cirrhosis. Check LFTs. |
| Thiamine | 100 mg PO/IM daily (higher in at-risk) | Prevention of Wernicke’s; all with heavy use | Give before any carbohydrate load in undernourished patients. Parenteral Pabrinex in high-risk withdrawal. |
Clinical Decision Pathway
A practical, question-based approach to alcohol use disorder in a 15-minute primary care slot. Work through the questions in order — each answer narrows the plan to something you can implement at the same visit.
Withdrawal Management in Primary Care
Alcohol withdrawal is a predictable, time-limited syndrome. Most patients with mild-to-moderate withdrawal can be managed safely in the community with appropriate supervision and a structured benzodiazepine regimen. Severe withdrawal — seizures, delirium tremens, autonomic instability — requires inpatient care. Knowing where the line sits is the core skill for community alcohol use disorder care.
Use the CIWA-Ar scale to assess withdrawal severity and guide benzodiazepine dosing. A score under 10 typically does not require pharmacotherapy; 10–18 can be managed with symptom-triggered dosing; 19 and above is severe and often warrants admission.
Strong Rec High Evidence ASAM 2020Manage mild-to-moderate withdrawal in the community with a short, symptom-triggered benzodiazepine course. Chlordiazepoxide tapers (e.g., 20–50 mg QID on day 1, tapering over 5–7 days) are widely used; diazepam and lorazepam are alternatives. Use lorazepam when significant hepatic impairment is present.
Strong Rec High Evidence ASAM 2020Prescribe thiamine 100 mg daily (oral or IM) for at least 2–4 weeks in all patients with heavy alcohol use, alongside folate and a multivitamin. Give thiamine before any glucose load in the undernourished patient to prevent precipitating Wernicke’s encephalopathy.
Strong Rec Moderate Evidence ASAM 2020Refer for inpatient withdrawal management if the patient has a history of seizures or delirium tremens, autonomic instability, severe intercurrent illness, a limited support network, or inability to attend daily review. Do not attempt community detox in these scenarios.
Strong Rec Moderate Evidence ASAM 2020Initiate pharmacotherapy for relapse prevention during or immediately after withdrawal. The transition from detox to no medication is the highest-risk period for relapse; linking the two is one of the most effective changes a primary care clinician can make in alcohol use disorder care.
Strong Rec Moderate Evidence VA/DoD 2021Triage: Who Can Be Managed in the Community?
| Feature | Community Detox Appropriate | Inpatient Preferred | Why It Matters |
|---|---|---|---|
| Prior withdrawal history | Mild withdrawal only | Seizures or DTs at any point | Kindling effect increases each episode’s severity |
| CIWA-Ar score | Under 15 sustained | 15+ or rising rapidly | Risk of progression to delirium tremens |
| Comorbidities | Stable | Cirrhosis, CHF, pregnancy, psychosis | Intercurrent illness complicates management |
| Social support | Reliable adult supervisor; safe environment | Homeless, alone, chaotic environment | Monitoring is essential during days 2–4 |
| Concurrent substance use | Alcohol only, or light cannabis | Benzodiazepines, opioids, stimulants | Polysubstance withdrawal is harder to manage |
Evidence in Context
Where the major guidelines on alcohol use disorder agree, where they differ, and where the evidence is still maturing.
Where USPSTF, APA, and VA/DoD Agree
All three endorse routine primary care screening with a validated tool, DSM-5 criteria for diagnosis, brief intervention for risky use, and a first-line role for naltrexone and acamprosate in moderate-to-severe alcohol use disorder. They agree that psychosocial treatment should accompany pharmacotherapy and that abstinence is not a precondition for starting medication.
Where They Differ: Gabapentin and Topiramate
The VA/DoD guideline gives gabapentin and topiramate a stronger second-line endorsement, reflecting positive controlled trials in veteran populations. The APA guideline recommends them conditionally for patients who cannot take or do not respond to naltrexone or acamprosate. In practice, gabapentin is often used earlier for patients with prominent early-recovery anxiety or insomnia, while topiramate fits well when concurrent migraine is present. Both remain off-label for alcohol use disorder in most jurisdictions.
Naltrexone Versus Acamprosate: The Jonas Meta-Analysis
A widely cited 2014 JAMA meta-analysis found both agents reduce return to drinking, with modest differences in effect. Naltrexone more consistently reduces heavy drinking days; acamprosate more consistently supports ongoing abstinence. Both have a number-needed-to-treat in the single digits — comparable to or better than many other chronic disease medications routinely prescribed in primary care.
Brief Intervention: What It Actually Does
USPSTF reviews show a consistent, if modest, reduction in drinking volume after a single structured primary care conversation about alcohol. Effect sizes are larger for risky drinkers than for those with established severe disease. The intervention is under 15 minutes, bills as a counselling visit in many systems, and does not require specialty training — yet fewer than 1 in 5 eligible patients currently receives one.
What We Still Don’t Know
The optimal duration of pharmacotherapy is not well-established beyond 6–12 months, and long-term outcome data are limited. Predictors of response to naltrexone versus acamprosate remain imprecise, though OPRM1 genotype may inform choice in selected patients. The role of emerging agents such as baclofen is still contested, with heterogeneous evidence and significant regional variation in use. Digital-first interventions (e.g., app-based CBT) are expanding rapidly but remain heterogeneous in regulatory status and quality.
References
- 1.US Preventive Services Task Force. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(18):1899–1909. doi:10.1001/jama.2018.16789
- 2.Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86–90. doi:10.1176/appi.ajp.2017.1750101
- 3.Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings: A Systematic Review and Meta-analysis. JAMA. 2014;311(18):1889–1900. doi:10.1001/jama.2014.3628
- 4.The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020;14(3S Suppl 1):1–72. doi:10.1097/ADM.0000000000000668
- 5.US Department of Veterans Affairs / Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. 2021. healthquality.va.gov/guidelines/MH/sud
- 6.Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. Arch Intern Med. 1998;158(16):1789–1795. doi:10.1001/archinte.158.16.1789
How to Read the Evidence Tags
Every recommendation in this article on alcohol use disorder carries two tags for recommendation strength and evidence quality, plus a source tag. These are Medaptly’s own simplified interpretations designed for rapid bedside use.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | Benefit is less certain — individualise to the patient. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |